Oseltamivir-Resistant Strains of Seasonal Influenza Found in North America and Europe
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Oseltamivir-Resistant Strains of Seasonal Influenza Found in North America and Europe

NEW YORK -- February 22, 2008 -- The World Health Organization (WHO) has reported higher rates of seasonal influenza A(H1N1) resistant to oseltamivir (Tamiflu) compared to previous seasons in various areas of four European countries, Canada, and the United States.

The initial report comes after Norway notified the WHO, under the International Health Regulations, that a high rate of A(H1N1) virus isolates had tested positive for oseltamivir resistance. Norwegian officials reported that the mutation was present in 12 of 16, or 75 percent of viruses isolated in that country from patients in November and December.

Among Britain, Denmark, France, and Norway, the four European countries reporting cases of the mutant virus known as influenza A(H1N1 H274Y), the Norwegian rate was the highest. Overall, the mutant form was found in 19 of the viruses isolated from 148 patients, or 13 percent, in a monitoring system that the European Center for Disease Prevention and Control runs in 10 European countries. Excluding Norway, that percentage fell to 5 percent.

In January, Alicia Fry, MD, MPH, Centers for Disease Control and Prevention (CDC), Atlanta, told The New York Times that the oseltamivir-resistant strain was found in 9 of 237, or 3.8 percent of US patients from whom influenza type A and B viruses were isolated. All 9 cases were in the A(H1N1) category.

As of February 9, 2008, 4.6% of all influenza viruses analysed by CDC this season have been found to be resistant to oseltamivir. Of those, 8.1% of A(H1N1) viruses have been resistant to oseltamivir. No oseltamivir-resistant influenza A(H3N2) or B viruses have been found in the United States this season.

The limited information currently available does not show clustering in particular age groups nor does it suggest that infections caused by the resistant strain are more severe. The WHO is compiling information to determine the public health impact of this data.

Despite the findings, officials from the WHO and the United States confirmed that there are no immediate plans to recommend changes in the use of oseltamivir because the incidence of the mutant virus is still small. CDC and the Advisory Committee on Immunization Practices (ACIP) recommend that oseltamivir or another antiviral, zanamivir (Relenza) can be used for the treatment and prevention of influenza in the United States this season. In addition, officials stated that immunization with this season's influenza vaccine remains effective, including for the prevention of illness due to the oseltamivir-resistant A(H1N1) virus.

SOURCE: World Health Organization, The New York Times, Centers for Disease Control and Prevention

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities